RxDoctor Payments Data

William Waller, MD

Dermatology · Hattiesburg, MSNPI 1053592840

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.5% of the total across 1,102 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 46 manufacturers, the largest accounting for just 22.4% — the pattern of someone who eats at a lot of different presentations.

$18,664in general payments, 2019–2025

Across 1,102 payments — averaging $16.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Novartis$2K
  • Merz North America, Inc.$1K
  • Sanofi$1K
  • Johnson & Johnson$1K
  • Sun Pharmaceutical Industries Inc.$943
  • plus $8K from 40 others

What the payments were for

  • Food & beverage$18,19597%
  • Education$4693%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,664 in reported general payments places this provider in the 80th percentile of 78 dermatology providers in Mississippi.

See all dermatology providers in Mississippi

Medicare billing

Part B allowed, 2024
$558,879
Medicare patients
1,174
Services billed
11,643

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast27$135,522
Ketoconazole314$5,196
Tacrolimus30$4,519
Dapsone40$3,586
Betamethasone Valerate54$3,567
Metronidazole48$2,407
Triamcinolone Acetonide175$2,234
Clobetasol Propionate60$2,001
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc49$1,551
Fluorouracil21$1,426
Clindamycin Phosphate41$1,379
Betamethasone Dipropionate33$1,279
Ciclopirox27$1,228
Mometasone Furoate61$1,102
Hydroxychloroquine Sulfate20$973

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$495$135,52227 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 78 dermatology providers in Mississippi.

Other dermatology in Hattiesburg

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →